Navigation Links
Could a protein be linked to heart attacks?
Date:9/3/2014

OTTAWA, September 3, 2014 A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact on cholesterol.

The team found that levels of the protein PCSK9 were elevated in the blood of patients having an acute heart attack, but not in those who never had a heart attack or who had recovered from one previously. The results were replicated in two separate groups of patients, all of whom have coronary artery disease but were not taking a cholesterol-lowering statin drug.

Published in the journal PLOS One, the findings point to an important question: "Are PCSK9 levels elevated shortly before you get a heart attack?" asks Dr. Stewart, principal investigator in the Ruddy Canadian Cardiovascular Genetics Centre at the Ottawa Heart Institute. "If levels only go up after, that would suggest a side effect of the heart attack. But if they go up before, that suggests it might trigger the event, or make it worse."

The Heart Institute researchers first identified the PCSK9 link to heart attacks using blood samples from patients enrolled in the Ottawa Heart Genomics Study. They then confirmed these results in a group of patients from Emory University in Atlanta, Georgia. Again, they found elevated PCSK9 levels in samples taken from patients at the time of acute heart attack, but not in samples taken from patients with a history of heart attack or from those with coronary artery disease who never had a heart attack.

The medical community and pharmaceutical companies are already highly interested in PCSK9 for its effects on LDL cholesterol. PCSK9 increases levels of LDL cholesterol in the bloodstream by reducing the ability of liver cells to remove and destroy it. Research indicates that blocking the effects of PCSK9 may offer a new way to substantially lower LDL cholesterol.

Several pharmaceutical companies have invested heavily in drugs to block PCSK9. The potential market is estimated to be in the billions of dollars because they lower cholesterol in a manner that is independent of the widely-prescribed statin drugs. In industry-sponsored clinical trials, these new drugs are looking to be effective in reducing LDL cholesterol levels. The link of PCSK9 to the event of a heart attack provides important new information about this protein that has seen such heavy investment.


'/>"/>

Contact: Vincent Lamontagne
vlamontagne@ottawaheart.ca
613-899-6760
University of Ottawa Heart Institute
Source:Eurekalert

Related biology news :

1. Heart-powered pacemaker could one day eliminate battery-replacement surgery
2. New test could help track down and prosecute terrorists
3. New antibiotic could make food safer and cows healthier
4. BPA could affect reproductive capabilities, cause infection of the uterus
5. Key to immune system disease could lie inside the cheek
6. New analysis of premature infants heartbeats, breathing could be cues for leaving NICU
7. Tiny electrical sensors could signal faster MRSA diagnosis
8. Corals could survive a more acidic ocean
9. Early warning system for seizures could cut false alarms
10. Rapid method of assembling new gene-editing tool could revolutionize genetic research
11. 800-year-old farmers could teach us how to protect the Amazon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology: